Baseline and Serial Measurements of Galectin-3 in Patients with Heart Failure: Relationship to Prognosis and Effect of Treatment with Valsartan in the Val-HeFT

Galectin-3 levels are elevated in a substantial proportion of patients with HF, particularly those with more severe HF and renal dysfunction. Galectin-3 increased over time in this cohort, and the increase was independently associated with worse outcomes. Valsartan use was associated with a reduction in hospitalizations for HF in patients with low galectin-3, but not in those with higher levels of galectin-3.